GeneTex

  • Country / Location Selection

United States (US)

DRAK1 peptide

Cat. No. GTX28453

Application

 Neutralizing/Inhibition

Species

 Human
Package
50 μg ($139)
See all DRAK1 products

APPLICATION

Application Note

The peptide is used for blocking the activity of DRAK1 (GTX28418). Incubatingthe peptide with equal volume of antibody for 30 min at 37ºC usually completely blocks theantibody activity in Western blotting.

PROPERTIES

Form

Liquid

Buffer

PBS, 0.1% BSA

Preservative

0.02% Sodium azide

Storage

Store the peptide at -20ºC, stable for one year.

Concentration

0.20 mg/ml (Please refer to the vial label for the specific concentration.)

Conjugation

Unconjugated

Note

For laboratory research use only. Not for any clinical, therapeutic, or diagnostic use in humans or animals. Not for animal or human consumption.

Purchasers shall not, and agree not to enable third parties to, analyze, copy, reverse engineer or otherwise attempt to determine the structure or sequence of the product.

TARGET

Synonyms

Serine/Threonine Kinase 17A , Drak1 , Stk17A

Background

This gene is a member of the DAP kinase-related apoptosis-inducing protein kinase family and encodes an autophosphorylated nuclear protein with a protein kinase domain. The protein has apoptosis-inducing activity. [provided by RefSeq]

Research Area

REFERENCE

There are currently no references for DRAK1 peptide (GTX28453). Be the first to share your publications with this product.
Submit a Reference

REVIEW

There are currently no reviews for DRAK1 peptide (GTX28453). Be the first to share your experience with this product.
Submit a Review
SDS
PBS.pdf
Sodium Azide.pdf
Package List Price ($)
$ 139